AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11110418 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving HSV‐tk/GCV gene therapy)
Number of subjects: 13
Study 8681594 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 98
Study 8681594 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 98
Study 8681594 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and Midazolam
Number of subjects: 98
Study 1922908 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 0.5 mg/kg body weight (Study 1)
Number of subjects: 14
Study 1922908 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 1.0 mg/kg body weight (Study 2)
Number of subjects: 14
Study 1922908 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (both studies)
Number of subjects: 14
Study 6802019 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.3 mg)
Number of subjects: 50
Study 6802019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg)
Number of subjects: 50
Study 29615172 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with adjunctive mitomycin C
Number of subjects: 60
Study 29615172 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy without adjunctive mitomycin C
Number of subjects: 60
Study 25819076 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 124
Study 25819076 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 124
Study 24669014 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF)
Number of subjects: 230
Study 24669014 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction TPF in cN+ patients with low GDF15 expression
Number of subjects: 230
Study 24669014 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction TPF in cN- patients with high GDF15 expression
Number of subjects: 230
Study 24669014 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased GDF15 expression in OSCC lines
Number of subjects: 230
Study 24669014 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of GDF15
Number of subjects: 230
Study 22823552 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-delivered medication therapy management (MTM) intervention
Number of subjects: 0
Study 22823552 — intervention group
Group type: EXPERIMENTAL
Intervention: MTM visits scheduled separately from other clinic appointments
Number of subjects: 0
Study 22823552 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider response to pharmacist recommendations
Number of subjects: 0
Study 20516309 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston brace worn for more than twelve hours per day
Number of subjects: 100
Study 20516309 — intervention group
Group type: COMPARATOR
Intervention: Boston brace worn for fewer than seven hours per day
Number of subjects: 100
Study 20516309 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston brace wear (general)
Number of subjects: 100
Study 20516309 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston brace wear
Number of subjects: 100
Study 18544146 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.03 mcg.kg(‐1).min(‐1)
Number of subjects: 54
Study 18544146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 15813839 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intervention (academic group detailing by a gastroenterologist and reinforcement by pharmacists)
Number of subjects: 581
Study 15813839 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intervention
Number of subjects: 581
Study 15813839 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity intervention (guidelines, patient-lists, and toolkit)
Number of subjects: 581
Study 15813839 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 581
Study 12150231 — intervention group
Group type: EXPERIMENTAL
Intervention: Study 1
Number of subjects: 0
Study 12150231 — intervention group
Group type: EXPERIMENTAL
Intervention: Study 2
Number of subjects: 0
Study 10468257 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse contour cardiac output (PCCO)
Number of subjects: 12
Study 10468257 — intervention group
Group type: COMPARATOR
Intervention: Thermodilution cardiac output (TDCO)
Number of subjects: 12
Study 10468257 — intervention group
Group type: COMPARATOR
Intervention: Transcardiopulmonary cardiac output (TCPCO)
Number of subjects: 12
Study 7834970 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy (100% humidified at 101/min for 8-10 h prior to ultrasound)
Number of subjects: 58
Study 7834970 — intervention group
Group type: COMPARATOR
Intervention: Control - no oxygen
Number of subjects: 58
Study 1972836 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA 2% cream
Number of subjects: 10
Study 1972836 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA 5% cream
Number of subjects: 10
Study 25075 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 10
Study 25075 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 10
Study 25075 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (300 mg)
Number of subjects: 10
Study 25075 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (100 mg)
Number of subjects: 10
Study 25075 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (100 mg)
Number of subjects: 10
Study 25075 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg)
Number of subjects: 10
Study 25075 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (10 mg)
Number of subjects: 10
Study 31523169 — intervention group
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao (YB) treatment
Number of subjects: 60
Study 27990643 — intervention group
Group type: EXPERIMENTAL
Intervention: CN-105 (active treatment)
Number of subjects: 48
Study 27990643 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 48
Study 26030115 — intervention group
Group type: EXPERIMENTAL
Intervention: Horticultural therapy (HT)
Number of subjects: 49
Study 26030115 — intervention group
Group type: COMPARATOR
Intervention: Nonhorticultural occupational therapy (OT)
Number of subjects: 49
Study 23343964 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal argon plasma coagulation (APC)
Number of subjects: 101
Study 23343964 — intervention group
Group type: COMPARATOR
Intervention: Peroral argon plasma coagulation (APC)
Number of subjects: 101
Study 21865980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca‐gluconate powder supplementation
Number of subjects: 99
Study 21865980 — intervention group
Group type: COMPARATOR
Intervention: Standard feeds (Control)
Number of subjects: 99
Study 18786982 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP for 4 weeks
Number of subjects: 100
Study 18786982 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic CPAP for 4 weeks
Number of subjects: 100
Study 17004075 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal screw fixation
Number of subjects: 47
Study 17004075 — intervention group
Group type: COMPARATOR
Intervention: Cast immobilisation
Number of subjects: 47
Study 15329423 — intervention group
Group type: EXPERIMENTAL
Intervention: CardioWest Total Artificial Heart
Number of subjects: 116
Study 15329423 — intervention group
Group type: COMPARATOR
Intervention: Control (no artificial heart)
Number of subjects: 116
Study 11158809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5% ophthalmic solution
Number of subjects: 104
Study 11158809 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 104
Study 9651141 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 14
Study 9651141 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 14
Study 7660237 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Rehabilitation Concepts system
Number of subjects: 67
Study 7660237 — intervention group
Group type: COMPARATOR
Intervention: Dual inclinometry
Number of subjects: 67
Study 7660237 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Rehabilitation Concepts with improved stabilization techniques
Number of subjects: 67
Study 2695155 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram/min of sulprostone until delivery
Number of subjects: 85
Study 2695155 — intervention group
Group type: COMPARATOR
Intervention: 1500 micrograms of sulprostone in 8 hours followed by another identical course if delivery did not occur within 24 hours
Number of subjects: 85
Study 2695155 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (1 microgram/min and 1500 micrograms in 8 hours)
Number of subjects: 85
Study 187356 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (300 mug)
Number of subjects: 0
Study 187356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31220560 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen capsules (BSC)
Number of subjects: 60
Study 31220560 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 60
Study 28714097 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based interpersonal psychotherapy (FB-IPT)
Number of subjects: 29
Study 28714097 — intervention group
Group type: COMPARATOR
Intervention: Family-based health education (FB-HE)
Number of subjects: 29
Study 25503617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU) administered twice daily for 1 week
Number of subjects: 23
Study 25503617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (48 IU) administered twice daily for 1 week
Number of subjects: 23
Study 25503617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (72 IU) administered twice daily for 1 week
Number of subjects: 23
Study 25503617 — intervention group
Group type: COMPARATOR
Intervention: Combined oxytocin groups vs placebo
Number of subjects: 23
Study 22471951 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 0
Study 21646616 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine with Bevacizumab (CG)
Number of subjects: 315
Study 21646616 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine without Bevacizumab (C)
Number of subjects: 315
Study 21646616 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine and Bevacizumab (CB)
Number of subjects: 315
Study 21646616 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine and Bevacizumab plus Mitomycin (CBM)
Number of subjects: 315
Study 19351734 — intervention group
Group type: EXPERIMENTAL
Intervention: Arzoxifene 20 mg/d
Number of subjects: 331
Study 19351734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 16724896 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgicel (oxidized cellulose) used to seal nephrostomy tract in ten patients.
Number of subjects: 20
Study 16724896 — intervention group
Group type: COMPARATOR
Intervention: Control group (ten patients) with nephrostomy tracts left unsealed.
Number of subjects: 20
Study 16724896 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups regarding decrease in hematocrit.
Number of subjects: 20
Study 16724896 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of extravasation from nephrostomy tract between groups.
Number of subjects: 20
Study 12875313 — intervention group
Group type: EXPERIMENTAL
Intervention: Climbers (n = 9)
Number of subjects: 27
Study 12875313 — intervention group
Group type: COMPARATOR
Intervention: Rowers (n = 9)
Number of subjects: 27
Study 12875313 — intervention group
Group type: COMPARATOR
Intervention: Leg trained athletes (n = 9)
Number of subjects: 27
Study 10568909 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical methods for early stopping in clinical trials
Number of subjects: 0
Study 10568909 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangular test method of early stopping
Number of subjects: 0
Study 8960814 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and fitness tracking
Number of subjects: 2
Study 8960814 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fitness level (VO2max)
Number of subjects: 2
Study 8960814 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive lifestyle
Number of subjects: 2
Study 8960814 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2max levels
Number of subjects: 2
Study 1756116 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA phototherapy (340‐400 nm)
Number of subjects: 31
Study 1756116 — intervention group
Group type: COMPARATOR
Intervention: UVA and UVB phototherapy (300‐400 nm)
Number of subjects: 31
Study 1756116 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of UVA (80‐160 J/cm2; 340‐440 nm) after treatment
Number of subjects: 31
Study 6187065 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide retard (DR) 2 X 300 mg/day
Number of subjects: 10
Study 6187065 — intervention group
Group type: COMPARATOR
Intervention: Propranolol retard (PR) 1 X 160 mg/day
Number of subjects: 10
Study 6187065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3916850 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 20
Study 3916850 — intervention group
Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 20
Study 31606753 — intervention group
Group type: EXPERIMENTAL
Intervention: D-fortified sunflower oil (500 IU/30 g)
Number of subjects: 65
Study 31606753 — intervention group
Group type: COMPARATOR
Intervention: Unfortified sunflower oil
Number of subjects: 65
Study 29300708 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (ROP)
Number of subjects: 153
Study 29300708 — intervention group
Group type: COMPARATOR
Intervention: Saline (NS)
Number of subjects: 153
Study 27575992 — intervention group
Group type: EXPERIMENTAL
Intervention: HB-C (home-based computer vergence/accommodative therapy)
Number of subjects: 204
Study 27575992 — intervention group
Group type: EXPERIMENTAL
Intervention: HB-PU (home-based near target push-up therapy)
Number of subjects: 204
Study 27575992 — intervention group
Group type: COMPARATOR
Intervention: HB-P (home-based placebo treatment)
Number of subjects: 204
Study 23829316 — intervention group
Group type: EXPERIMENTAL
Intervention: Narratives with no acknowledgment of personal responsibility
Number of subjects: 0
Study 23829316 — intervention group
Group type: EXPERIMENTAL
Intervention: Narratives with moderate acknowledgment of personal responsibility
Number of subjects: 0
Study 23829316 — intervention group
Group type: COMPARATOR
Intervention: Control group (unrelated story)
Number of subjects: 0
Study 21450579 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational counselling (MC) intervention group
Number of subjects: 141
Study 21450579 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) control group
Number of subjects: 141
Study 20395684 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5-10 mg/day
Number of subjects: 290
Study 20395684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 18315940 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular IFNbeta‐1a (Avonex) 30 microg once weekly
Number of subjects: 136
Study 18315940 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous IFNbeta‐1a (Rebif) 44 microg three times per week
Number of subjects: 136
Study 18315940 — intervention group
Group type: EXPERIMENTAL
Intervention: NAb+ patients
Number of subjects: 136
Study 18315940 — intervention group
Group type: EXPERIMENTAL
Intervention: NAb- patients
Number of subjects: 136
Study 15726299 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 662
Study 15726299 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 662
Study 15726299 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 662
Study 14870956 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 14870956 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0
Study 10325723 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured nurse-led discharge package (20 minute patient education programme and self management plan)
Number of subjects: 160
Study 10325723 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard discharge procedure)
Number of subjects: 160
Study 7813335 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent obtained 24 to 72 hours before the procedure
Number of subjects: 60
Study 7813335 — intervention group
Group type: COMPARATOR
Intervention: Informed consent obtained immediately before the procedure
Number of subjects: 60
Study 1955129 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency esophageal variceal sclerotherapy
Number of subjects: 72
Study 1955129 — intervention group
Group type: COMPARATOR
Intervention: Elective esophageal variceal sclerotherapy
Number of subjects: 72
Study 1955129 — intervention group
Group type: COMPARATOR
Intervention: Emergency endoscopy alone
Number of subjects: 72
Study 6759457 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilopaque
Number of subjects: 45
Study 6759457 — intervention group
Group type: COMPARATOR
Intervention: Telepaque
Number of subjects: 45
Study 30944133 — intervention group
Group type: EXPERIMENTAL
Intervention: Chou-Ling-Dan (CLD) granules for 5 days
Number of subjects: 318
Study 30944133 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir for 5 days
Number of subjects: 318
Study 30944133 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 318
Study 27870567 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 189
Study 27870567 — intervention group
Group type: COMPARATOR
Intervention: Minimally Enhanced Usual Care
Number of subjects: 189
Study 27870567 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness skill of observing (MBCT)
Number of subjects: 189
Study 27250730 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on breastfeeding-optimization program
Number of subjects: 784
Study 27250730 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 784
Study 24902492 — intervention group
Group type: EXPERIMENTAL
Intervention: South Asian patients with type 2 diabetes
Number of subjects: 1978
Study 24902492 — intervention group
Group type: EXPERIMENTAL
Intervention: South Asian patients with type 2 diabetes (adjusted)
Number of subjects: 1978
Study 24902492 — intervention group
Group type: COMPARATOR
Intervention: White European patients with type 2 diabetes
Number of subjects: 1978
Study 22009665 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 90
Study 22009665 — intervention group
Group type: COMPARATOR
Intervention: No video (Control)
Number of subjects: 90
Study 19444734 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Naltrexone Therapy
Number of subjects: 63
Study 19444734 — intervention group
Group type: COMPARATOR
Intervention: Compliance Enhancement (Control)
Number of subjects: 63
Study 19444734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cannabis use
Number of subjects: 63
Study 19444734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive behavioral therapy
Number of subjects: 63
Study 17472953 — intervention group
Group type: EXPERIMENTAL
Intervention: Stork Test on the support side (2-point scale)
Number of subjects: 33
Study 17472953 — intervention group
Group type: EXPERIMENTAL
Intervention: Stork Test on the support side (3-point scale)
Number of subjects: 33
Study 14679382 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition counselling for children and parents
Number of subjects: 98
Study 14610711 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus tracking (group B)
Number of subjects: 71
Study 14610711 — intervention group
Group type: COMPARATOR
Intervention: Fixed delay (group F)
Number of subjects: 71
Study 14610711 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study 10726104 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4 g/day of LC n‐3 PUFA
Number of subjects: 9
Study 10726104 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 9
Study 10726104 — intervention group
Group type: COMPARATOR
Intervention: MUFA/SFA content
Number of subjects: 9
Study 10726104 — intervention group
Group type: EXPERIMENTAL
Intervention: LC n‐3 PUFA diet
Number of subjects: 9
Study 10726104 — intervention group
Group type: COMPARATOR
Intervention: Meal MUFA/SFA study
Number of subjects: 9
Study 8530611 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium bicarbonate (KHCO3, 2 meq/kg/day in divided doses)
Number of subjects: 14
Study 8530611 — intervention group
Group type: COMPARATOR
Intervention: Control (potassium chloride, 25 meq/day)
Number of subjects: 14
Study 1837554 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic GIFT (group 1)
Number of subjects: 131
Study 1837554 — intervention group
Group type: COMPARATOR
Intervention: Hysteroscopic GIFT (group 2)
Number of subjects: 131
Study 6211981 — intervention group
Group type: COMPARATOR
Intervention: Ticarcillin plus amikacin (T + A)
Number of subjects: 191
Study 6211981 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam plus amikacin (M + A)
Number of subjects: 191
Study 31493863 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and exercise (strengthening and neuromuscular control) targeting gluteal muscles
Number of subjects: 361
Study 31493863 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 361
Study 31493863 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching
Number of subjects: 361
Study 31493863 — intervention group
Group type: EXPERIMENTAL
Intervention: Range of motion exercises
Number of subjects: 361
Study 31493863 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal modalities
Number of subjects: 361
Study 31493863 — intervention group
Group type: EXPERIMENTAL
Intervention: Taping
Number of subjects: 361
Study 31493863 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrotherapy
Number of subjects: 361
Study 31493863 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injections
Number of subjects: 361
Study 31493863 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain severity scales
Number of subjects: 361
Study 31493863 — intervention group
Group type: EXPERIMENTAL
Intervention: Single leg stance
Number of subjects: 361